返回 Agenda
Session Chair(s)
Linda J. Scarazzini, MD, RPH
Vice President, Pharmacovigilance and Patient Safety
AbbVie, United States
Speaker(s)
Peter Richard Arlett, MD, FFPM, FRCP
European Medicines Agency, Netherlands
Head Data Analytics and Methods Task Force
Scientific Challenges for Post-Authorisation Safety and Efficacy Studies
Corinne de Vries, PHD, MA, MSC
European Medicines Agency, Netherlands
EMA liaison official to the US FDA
In the World of Expedited Pathways, will PAES and PASS substantiate Benefit-Risk?
Ryan Dean Kilpatrick, PHD
AbbVie, United States
Global Head, Epidemiology
PASS – Is the Ongoing Surveillance a Blessing or a Curse?
Magdalena Matusiak, MPHARM
KCR SA, Poland
Manager, Clinical Development; Pharmacovigilance Team Lead